The North America Intravascular Lithotripsy (IVL) market size is expected to be valued at US$ 950.3 million in 2026 and projected to reach US$ 2,558.8 million growing at a CAGR of 15.2% between 2026 and 2033. This exceptional growth trajectory is underpinned by the U.S.' position as the global epicenter of IVL clinical development and commercial adoption, supported by landmark FDA regulatory clearances, the world's highest per-capita PCI procedural volumes, and the landmark Johnson & Johnson acquisition of Shockwave Medical that has amplified commercial scale across the region.

The CDC estimates cardiovascular diseases caused nearly 695,000 fatalities annually in the U.S., while the American Heart Association (AHA) projects that approximately 45.1% of U.S. adults will have some form of cardiovascular disease by 2035, which directly expands the population of patients with coronary and peripheral calcification requiring advanced interventional solutions. The historical CAGR of 13.5% between 2020 and 2025 confirms accelerating hospital adoption following FDA clearance milestones, with expanding CMS reimbursement support and the ongoing outpatient vascular procedure volume shift expected to sustain the market's double-digit trajectory.

Drivers - Calcific Cardiovascular Disease Burden and PCI Procedural Volume Scale

The North America IVL market benefits from a structurally enormous and growing demand base rooted in the region's high burden of calcific cardiovascular disease and the concentrated procedural volume of interventional cardiology in the U.S. The ACC National Cardiovascular Data Registry (NCDR) documents over 1.2 million percutaneous coronary interventions performed annually in the U.S., of which approximately 18-20% involve severely calcified coronary lesions suitable for IVL treatment, per data published in JACC: Cardiovascular Interventions.

The AHA projects that by 2035, approximately 45.1% of U.S. adults will have some form of cardiovascular disease, directly expanding the long-term addressable patient base for coronary and peripheral IVL interventions. This demographic and epidemiological reality creates a durable, economically recession-resistant structural demand driver that sustains IVL procedural volume growth independent of broader healthcare spending cycles across North America.

FDA Regulatory Leadership and the DISRUPT Trial Clinical Evidence Platform

The FDA's robust and well-established regulatory framework for IVL built through 510(k) clearances under the Medical Device User Fee and Modernization Act (MDUFMA) has been the foundational enabler of North America's IVL market leadership, providing hospitals and interventional cardiologists with the institutional confidence to adopt IVL systems at scale. The DISRUPT CAD III pivotal trial enrolling 431 patients across 47 global sites demonstrated a 92.4% procedural success rate in severely calcified coronary lesions and an in-hospital MACE rate of just 0.8%, establishing the global clinical evidence standard for coronary calcium modification. For peripheral applications, DISRUPT PAD III demonstrated primary patency of 65.7% at 3 years versus 47.9% for conventional balloon angioplasty, a differentiation that has driven FDA clearance and rapid vascular surgery adoption. These FDA-validated clinical evidence packages have directly driven ACC/AHA calcium modification guideline endorsement, creating a self-reinforcing clinical-commercial adoption cycle across the North America IVL market.

Restraints - CMS Reimbursement Variability and Hospital Cost Justification Requirements

Despite a favorable U.S. regulatory environment, inconsistent CMS and commercial payer reimbursement for IVL procedures creates material adoption friction, particularly in budget-constrained community hospital settings that represent a large share of total U.S. PCI volume. IVL catheter list prices of approximately US$ 3,000-5,000 per single-use device generate significant hospital value analysis committee scrutiny, and while Medicare's National Coverage Determination framework covers coronary revascularization broadly, reimbursement parity between IVL and established atherectomy devices remains inconsistent across Medicare Advantage and commercial payer contracts. These reimbursement complexities add institutional decision-making cycles that delay IVL program adoption beyond academic and high-volume cardiac centers in the U.S. market.

IVUS Penetration Gap and Operator Training Barriers in Community Settings

IVL's optimal clinical deployment requires intravascular imaging guidance, either IVUS or OCT, to assess calcium morphology and guide catheter sizing decisions. The ACC and the Society for Cardiovascular Angiography and Interventions (SCAI) endorse intravascular imaging for calcified lesion PCI, yet IVUS utilization in U.S. PCI procedures remains below 20% as of 2023, with rates substantially lower in community hospital settings. This imaging penetration gap creates a structural ceiling on IVL adoption beyond high-volume academic centers, where IVUS infrastructure and operator expertise are concentrated. Expanding IVL into the broader community hospital population, which handles the majority of U.S. PCI volume, requires simultaneous investment in IVUS adoption, operator training, and clinical education programs from IVL manufacturers.

Opportunities - Peripheral IVL: Fastest Growing Segment with a Structurally Underserved PAD Population

The peripheral IVL segment represents the fastest-growing commercial expansion opportunity within the North America market, where clinical evidence is now mature, but commercial penetration relative to total addressable procedural volume remains structurally nascent. The American Heart Association (AHA) estimates approximately 12 million Americans have peripheral arterial disease (PAD), with prevalence rising sharply among adults over 65, a demographic expanding rapidly across the U.S. and Canada. The DISRUPT PAD III trial demonstrated primary patency of 65.7% at 3 years versus 47.9% for conventional balloon angioplasty, a differentiation that has generated strong adoption among vascular surgery and interventional radiology teams at academic vascular centers. Shockwave Medical's (Johnson & Johnson) expanded FDA clearance for the S4 peripheral IVL catheter in 2024 has further extended the addressable peripheral lesion set. As commercial targeting expands from academic centers to community-based interventional radiology and outpatient endovascular suites across North America, the peripheral segment is positioned for compounding volume growth through 2033.

Ambulatory Surgical Center Expansion and the Outpatient Vascular Procedure Shift

The accelerating shift of cardiovascular and peripheral vascular procedures from inpatient hospital settings to ambulatory surgical centers (ASCs) represents a structurally significant growth opportunity for the North America IVL market and a competitive dynamic that favors manufacturers with flexible catheter-based solutions suited to outpatient procedural environments. CMS has progressively expanded its approved procedure list for ASC reimbursement to include peripheral vascular interventions, driving a substantial volume shift toward outpatient procedural sites. According to the Ambulatory Surgery Center Association (ASCA), over 5,700 Medicare-certified ASCs are operating across the U.S. as of 2023, with a growing number investing in cardiac and vascular catheterization capabilities. The lower overhead cost structure of ASCs amplifies the economic case for IVL adoption, as the cost savings from premium device utilization are more visible in the ASC cost accounting model. Manufacturers that develop ASC-focused sales strategies, simplified training programs, and outcome-based contracting models will capture first-mover advantages as this procedural site expansion accelerates through 2033.

Product Type Insights

Coronary Intravascular Lithotripsy Systems command the dominant position in the North America IVL market by product type, accounting for approximately 63% of total product type revenue in 2026. This leadership reflects the segment's foundational commercial trajectory in the U.S., the world's largest and most advanced coronary intervention market. The Shockwave Medical Shockwave C2+ coronary IVL catheter, the only FDA-cleared coronary IVL device at commercial scale, has driven category growth through compelling DISRUPT CAD III data, with a 92.4% procedural success rate in the most technically challenging calcified lesion subset.

The ACC NCDR documents over 1.2 million annual U.S. PCIs, of which approximately 18-20% involve severely calcified lesions, creating a large, structurally captive patient population. Peripheral IVL Systems represent the fast-growing product segment, driven by DISRUPT PAD III evidence and the FDA's 2024 expanded clearance for the Shockwave S4 peripheral IVL catheter.

Disease Indication Insights

Coronary Artery Disease (CAD) holds the leading position in the North America IVL market by disease indication, representing approximately 58% of total indication-segment revenue in 2026. CAD's dominance reflects IVL technology's foundational clinical development in the U.S.: the DISRUPT CAD trial series with DISRUPT CAD III enrolling 431 patients across 47 global sites established IVL's procedural efficacy in calcified coronary lesions and drove initial FDA clearance and physician adoption at scale.

The WHO estimates ischemic heart disease accounts for approximately 16% of total global mortality, and the CDC reports coronary artery disease affects over 18.2 million U.S. adults, sustaining a structurally enormous North American patient population requiring advanced coronary intervention. Peripheral Arterial Disease (PAD) is the fast-growing indication, propelled by DISRUPT PAD III evidence and accelerating commercialization across vascular surgery and interventional radiology practices in the U.S.

North America Intravascular Lithotripsy (IVL) Market Trends and Insights

North America leads the global intravascular lithotripsy (IVL) market, supported by advanced cardiovascular care infrastructure, favorable reimbursement policies, and early regulatory approvals that accelerated technology adoption. The region benefits from a high prevalence of coronary artery disease and peripheral artery disease, creating strong demand for calcium modification technologies during complex endovascular interventions.

Academic medical centers and high-volume catheterization laboratories continue to drive procedural adoption, supported by growing clinical evidence demonstrating the safety and effectiveness of IVL in heavily calcified lesions. Expansion of outpatient cardiovascular procedures and ambulatory surgery centers is further increasing access to IVL technologies. Continued investments by leading manufacturers, physician training initiatives, and integration of IVL into treatment algorithms are expected to sustain strong market growth across North America through the forecast period.

U.S. Intravascular Lithotripsy (IVL) Market Size

The U.S. accounts for 93% of the North American IVL market, making it the region’s largest revenue contributor. Market growth is driven by high volumes of percutaneous coronary interventions (PCI), increasing prevalence of calcified coronary lesions, and widespread availability of advanced catheterization laboratories. Favorable reimbursement from Medicare and commercial insurers has supported rapid physician adoption of IVL technologies in both coronary and peripheral vascular interventions. The presence of major industry participants, strong clinical trial activity, and growing utilization of calcium modification procedures continue to expand the addressable market. Increasing outpatient cardiovascular interventions are expected to further accelerate demand.

Canada Intravascular Lithotripsy (IVL) Market Size

Canada represents a smaller but rapidly expanding segment of the North American IVL market. Growth is supported by increasing adoption of advanced interventional cardiology procedures, expanding access to catheterization laboratories, and rising awareness of calcium modification techniques among healthcare providers. The country’s healthcare system continues to incorporate innovative cardiovascular technologies that improve outcomes in patients with heavily calcified arterial disease. Regulatory alignment with major international approvals has facilitated access to IVL systems, while growing physician experience is driving procedural confidence. As cardiovascular disease prevalence increases and hospital infrastructure advances, IVL utilization is expected to grow steadily across Canadian healthcare facilities.

The North America IVL market is highly concentrated, with Shockwave Medical (operating under Johnson & Johnson following its 2024 US$ 13.1 billion acquisition) commanding a dominant share of the coronary IVL segment through its proprietary Shockwave C2+ platform, the only FDA-cleared coronary IVL device at commercial scale. This creates a near-oligopolistic near-term competitive structure, though the pipeline is advancing:

Bolt Medical (Boston Scientific) and AVS Pulse, Inc. are progressing next-generation IVL platforms in clinical evaluation. Key competitive strategies include label expansion into new indications, physician training investment, ASC-focused go-to-market models, and outcome-based contracting with payers. The J&J acquisition is driving accelerated commercial investment and distribution scale-up across both coronary and peripheral IVL segments.

Key Developments

• May 2026: Johnson & Johnson announced the global launch of the Shockwave™ C2 Aero Coronary Intravascular Lithotripsy (IVL) Catheter, expanding its portfolio of calcium modification technologies for the treatment of severely calcified coronary artery disease.
• January 2025: Boston Scientific acquired Bolt Medical, Inc., a medical technology company specializing in intravascular lithotripsy (IVL) systems for the treatment of calcified coronary and peripheral artery disease. This strengthened Boston Scientific’s position in the vascular intervention market and expanded its portfolio of calcium modification technologies.